Actively Recruiting
Evaluating Safety, Tolerability, and Food Effects of CBT-248 in Healthy Adults with Chronic Pancreatitis
Led by Cibus Therapeutics, Inc. · Updated on 2026-10-29
32
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating CBT-248, an experimental medicine for chronic pancreatitis, a condition causing ongoing inflammation and damage to the pancreas that can lead to pain and digestion and blood sugar problems. This Phase 1 trial involves 32 healthy adults to assess side effects at various doses, measure how the medicine behaves in the body, and study whether taking it with food changes its effects. Participants are divided into four groups of eight six receive CBT-248 and two receive a placebo. Three groups receive one dose after fasting, involving clinic stays starting two days before dosing and follow-up visits on days four and six after dosing. The fourth group receives two doses on separate occasions one after fasting and one after a high-fat, high-calorie meal, with the second dose administered after safety and blood level reviews. Throughout the study, participants undergo blood tests, physical exams, heart activity monitoring, and vital sign checks. Side effects are continuously monitored from baseline to the end of the study. Pharmacokinetic measures include drug concentration and clearance over time. Participation includes clinic stays, follow-up visits, and safety assessments, lasting up to seven days per dosing period.
CONDITIONS
Brief Title
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Food Effect of CBT-248 in Healthy Adult Participants
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here